JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Terry, A. V.
Right arrow Articles by Menzaghi, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Terry, A. V., Jr.
Right arrow Articles by Menzaghi, F.

Vol. 301, Issue 1, 284-292, April 2002

Effects of (±)-4-{[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio}phenol Hydrochloride (SIB-1553A), a Selective Ligand for Nicotinic Acetylcholine Receptors, in Tests of Visual Attention and Distractibility in Rats and Monkeys

A. V. Terry, Jr. , V. B. Risbrough1 , J. J. Buccafusco and F. Menzaghi2

Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, Medical College of Georgia, Augusta, Georgia (A.V.T.); Alzheimer's Research Center and Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia (A.V.T., J.J.B.); Department of Veterans Affairs Medical Center, Augusta, Georgia (A.V.T., J.J.B.); and Merck Research Laboratories, La Jolla, California (V.B.R., F.M.)

Nicotine, a nonselective ligand for nicotinic acetylcholine receptors (nAChRs), has been shown to improve attention and reduce distractibility in humans. Although the numerous side effects induced by nicotine prevent its use as a therapeutic agent, it is hypothesized that subtype-selective nAChR ligands may offer a potential therapeutic benefit to humans with attention deficits. In this study, we evaluated the attention-enhancing properties of (±)-4-{[2-(1-methyl-2-pyrrolidinyl)ethyl]thio}phenol hydrochloride (SIB-1553A), a ligand selective for neuronal nAChRs with predominant activity at the human beta 4 subtype. SIB-1553A was evaluated in a test of attention (i.e., five-choice serial reaction time task or SRTT) and distractibility (i.e., delayed matching to sample task with distractor or DMTS-D) in adult rats and monkeys, respectively. SIB-1553A did not improve SRTT performance in normal rats, but reversed deficits induced by the N-methyl-D-aspartate (NMDA) antagonist dizocilpine. In the DMTS-D, SIB-1553A improved accuracy across several doses at the short delay intervals, which were affected most by distracting stimuli in adult monkeys. Subsequent testing with optimal doses for each monkey was also associated with significant improvements in DMTS-D accuracy at short delays, indicating the reproducibility of the drug effect. In both species, SIB-1553A had no significant effects on latencies for sample or choice selection and was not associated with adverse effects at efficacious doses. Although it remains to be further demonstrated, SIB-1553A may act through combined nicotinic and non-nicotinic mechanisms. Collectively, the present data suggest that in specific conditions SIB-1553A may improve certain aspects of attentional function in young adult rats and nonhuman primates without adverse side effects.


1 Present address: University of California, San Diego, CA 92093.

2 Present address: Arena Pharmaceuticals Inc., San Diego, CA 92121.


0022-3565/02/3011-0284$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
L. Azam and J. M. McIntosh
Characterization of Nicotinic Acetylcholine Receptors That Modulate Nicotine-Evoked [3H]Norepinephrine Release from Mouse Hippocampal Synaptosomes
Mol. Pharmacol., September 1, 2006; 70(3): 967 - 976.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
J. J. Buccafusco
Neuronal Nicotinic Receptor Subtypes: DEFINING THERAPEUTIC TARGETS
Mol. Interv., October 1, 2004; 4(5): 285 - 295.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. V. Terry Jr and J. J. Buccafusco
The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 821 - 827.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. S. Schneider, J. P. Tinker, F. Menzaghi, and G. K. Lloyd
The Subtype-Selective Nicotinic Acetylcholine Receptor Agonist SIB-1553A Improves Both Attention and Memory Components of a Spatial Working Memory Task in Chronic Low Dose 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Monkeys
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 401 - 406.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
E. J. Popke
From Anticholinesterase Toxicity to Alzheimer's Disease: Important Interactions of Cholinergic and NMDA Receptor Systems
Toxicol. Sci., April 1, 2003; 72(2): 185 - 187.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.